Duchenne dystrophy is a genetic and progressive muscle disease resulting in muscle weakness and loss of function of the muscle itself. Occurs by mutation of a gene for the protein dystrophin on the X chromosome. Women are usually only carriers of the mutation, and men suffer. In the early stages of the disease affected the lower limbs and pelvis, and as the disease progresses the disease affects the upper extremity and shoulder rim. Muscle wasting the replacement of muscle tissue by connective tissue, body fat and calcium deposition. The diagnosis of Duchenne muscular dystrophy is very complex and consists of a detailed medical history, detailed neurological treatment, laboratory tests, imaging studies, specific functional tests, methods of molecular genetics and muscle biopsy. Treatment of Duchenne muscular dystrophy requires a multidisciplinary approach, and includes drug therapy, surgical therapy and physiotherapy. No specific drug, but from medications used corticosteroid prednisone and many other supplements patients. Surgical procedures are performed with the onset of joint contractures and scoliosis of the spine. The most important physical therapy to slow the deterioration of muscle strength and function. On average about 12 years of age suffering from Duchenne muscular dystrophy become immobile and become bound to a wheelchair for life. As the disease progresses there are many complications, and are the most important in terms of cardiopulmonary pneumonia and acute heart failure. The lifespan of a person suffering from Duchenne muscular dystrophy is 30-35 years. As with many other genetic diseases, and for the Duchenne disease is recommended that genetic testing and genetic counseling. Numerous studies with the aim of discovering a cure for this disorder are now in progress, and the success recorded the discovery of drug codenamed PCT124 which is now in use under the name ataluren.